Are CB2 Receptors a New Target for Schizophrenia Treatment?

Autor(es)

Cortez, Isadora L. ^[1] ; Rodrigues da Silva, Naielly ^[1] ; Guimaraes, Francisco S. ^[1] ; Gomes, Felipe V. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Ribeirao Preto - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: FRONTIERS IN PSYCHIATRY; v. 11, OCT 30 2020.
• Citações Web of Science: 0

Resumo

Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptors are now proposed to play a role in several brain processes related to schizophrenia, such as modulation of dopaminergic neurotransmission, microglial activation, and neuroplastic changes induced by stress. Here, we reviewed studies describing the involvement of the CB2 receptor in these processes and their association with the pathophysiology of schizophrenia. Taken together, these pieces of evidence indicate that CB2 receptor may emerge as a new target for the development of antipsychotic drugs. (AU)

• Processo FAPESP: 17/24304-0 - Novas perspectivas no emprego de fármacos que modificam neurotransmissores atípicos no tratamento de transtornos neuropsiquiátricos
• Beneficiário: Francisco Silveira Guimaraes
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 18/17597-3 - O impacto do estresse sobre o sistema dopaminérgico é determinado pelo período crítico de plasticidade: implicações para a depressão e a esquizofrenia e o estudo de novos alvos farmacológicos
• Beneficiário: Felipe Villela Gomes
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores